University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
NCT Number: NCT02135432
The study is a randomized, double-blind, placebo-controlled, multiple-dose, pilot study of orally-administered ivacaftor in subjects with chronic obstructive pulmonary disease. Subjects will be administered the study drug ivacaftor 150 mg (or placebo) twice daily (BID).
Looking for future studies?
Notify Me40 year–65 year
All sexes
Interventional
Early Phase 1
Birmingham, Alabama, 35233, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients who have not been stable or have been hospitalized in the past 3 months with any clinically significant cardiac conditions.
Subjects with history of cancer (current or past, unless remote (>5years))except for localized non-melanomatous skin cancers History of Stroke/CVA History of myocardial infarction/acute coronary syndrome Cardiac Failure NYHC grade III-IV Diabetes Type I Uncontrolled Hypertension Primary or secondary pulmonary hypertension
-
Other names: Kalydeco
Time frame: baseline to 2 weeks
sweat analysis is measured by performing a sweat test in each participant. The primary analysis will compare the within group change in sweat chloride before (day 1) and after (day 14) ivacaftor or placebo administration and will be used to test the null hypothesis of no change in sweat chloride using a paired t-test unless the distributions are notably skewed, in which case the non-parametric Wilcoxon signed-rank test will be implemented due to small sample size.
Time frame: baseline to 2 weeks
Evaluate the efficacy of ivacaftor treatment in patients with COPD including measures of CFTR activity and clinical outcome as measured by change in nasal potential difference measurement in each group. These data will be used to test the null hypothesis of no change in nasal potential difference (ΔLow Chloride plus isoproterenol) using a paired t-test unless the distributions are notably skewed, in which case the non-parametric Wilcoxon signed-rank test will be implemented due to small sample size.
Time frame: baseline to 2 weeks
Number of adverse events per subject in each the Ivacaftor subjects and placebo subjects
Time frame: baseline to 2 weeks
Spirometry will be analyzed by ATS criteria, and the best of three reproducible efforts will be used to calculate FEV1 in comparison to Hankinson standards. The primary analysis will be the change in FEV1% from day 0 to day 14 within subject, and will be tested against the null hypothesis that no change occurs using a paired t-test unless the distributions are notably skewed, in which case the non-parametric Wilcoxon signed-rank test will be implemented due to small sample size.
Time frame: baseline to 2 weeks
University of Alabama at Birmingham
Other
A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05641207
Bronchial Diseases, Bronchitis
Beijing, Beijing Municipality, China
View Trial DetailsNCT06518473
Chronic Disease, Chronic Obstructive Pulmonary Disease
Al Mansurah, Egypt
View Trial DetailsNCT02811588
Chronic Disease, Chronic Obstructive Pulmonary Disease
Aachen, North Rhine-Westphalia, Germany
View Trial DetailsNCT03566667
Chronic Disease, Chronic Obstructive Pulmonary Disease
Örebro, Sweden
View Trial Details